96900

Actinotherapy (ultraviolet light)

Actinotherapy, also known as ultraviolet (UV) light therapy or phototherapy, is a specialized dermatological procedure involving the controlled exposure of the skin to ultraviolet radiation to treat a broad spectrum of cutaneous diseases. The CPT code 96900 specifically designates the administration of actinotherapy without the concurrent use of systemic or topical photosensitizing agents, distinguishing it from photochemotherapy (such as PUVA). During actinotherapy, either Ultraviolet B (UVB)—which includes broadband UVB (BBUVB) or narrowband UVB (NBUVB)—or Ultraviolet A (UVA) is emitted from specialized fluorescent lamps or light-emitting diodes (LEDs). The ultraviolet radiation penetrates the epidermis and dermis to exert localized immunomodulatory, anti-inflammatory, and anti-proliferative effects. These effects are particularly beneficial for arresting the hyperproliferation of keratinocytes seen in psoriasis, reducing the inflammatory cascade in atopic dermatitis and eczema, stimulating melanocyte activity in vitiligo, and inducing apoptosis of malignant T-cells in early-stage cutaneous T-cell lymphoma (mycosis fungoides). The procedure requires precise dosimetric calculations based on the patient's skin phototype (Fitzpatrick scale), prior exposure history, and clinical response. Typically administered in a specialized full-body phototherapy cabinet or via targeted handheld devices for localized areas, the patient undergoes a series of sessions, often two to three times per week. Before treatment begins, sensitive areas such as the eyes and male genitalia are meticulously protected with UV-blocking goggles and shielding to prevent acute phototoxicity and long-term adverse effects like cataracts or malignancy. The initial dose is usually determined by establishing the patient's minimal erythema dose (MED), after which the exposure time or intensity is gradually increased in subsequent sessions to maintain therapeutic efficacy. The success of actinotherapy relies heavily on strict adherence to the treatment protocol and ongoing clinical assessment by the dermatologist to mitigate risks of erythema, blistering, premature photoaging, and potential photocarcinogenesis. It is imperative that comprehensive documentation is maintained in the patient's medical record, detailing the specific wavelength utilized, the calculated dosimetry per session, cumulative UV exposure, and any adverse cutaneous reactions observed. This meticulous tracking ensures both the therapeutic optimization of the modality and compliance with established dermatological guidelines. When properly utilized, actinotherapy remains a cornerstone in the non-pharmacological management of recalcitrant dermatoses.

Clinical Indications

  • Moderate to severe plaque psoriasis unresponsive to topical treatments.
  • Atopic dermatitis (eczema) requiring systemic or non-topical intervention.
  • Vitiligo, for the purpose of inducing repigmentation.
  • Cutaneous T-cell lymphoma, specifically early-stage mycosis fungoides.
  • Severe generalized pruritus, including uremic pruritus or pruritus of hepatic origin.
  • Pityriasis rosea exhibiting severe symptoms or extensive coverage.
  • Lichen planus with extensive cutaneous involvement.

Procedure Steps

  1. Evaluate the patient's skin phototype using the Fitzpatrick scale to determine safe initial dosing.
  2. Establish the Minimal Erythema Dose (MED) if required by the specific phototherapy protocol.
  3. Calculate the precise UV light dosage and exposure duration based on established guidelines and the patient's prior response.
  4. Ensure the patient removes clothing to expose the affected areas while appropriately covering non-affected, sensitive regions.
  5. Provide and apply necessary protective gear, including UV-blocking goggles for the eyes and shielding for the male genitalia.
  6. Position the patient correctly within the phototherapy cabinet or position the targeted UV device over the specific localized lesion.
  7. Initiate the ultraviolet light exposure, strictly adhering to the calculated duration.
  8. Monitor the patient visually and audibly during the brief exposure period to identify any signs of discomfort or immediate adverse reactions.
  9. Conclude the session automatically via dosimeter or manual shut-off, and assist the patient from the unit.
  10. Examine the skin for immediate severe erythema and accurately document the session's dosimetry, exposure time, and cumulative UV exposure in the medical record.

Coding Guidelines

  • CPT 96900 is used exclusively for actinotherapy (ultraviolet light) administered without the use of an oral or topical photosensitizing agent.
  • Do not report 96900 in conjunction with 96910 (photochemotherapy with tar/petrolatum) or 96912 (photochemotherapy with psoralens, PUVA) for the same treatment session.
  • Only one unit of 96900 should be reported per session, regardless of the number of body areas treated or the total duration of the light exposure.
  • An Evaluation and Management (E/M) service is generally not reported on the same day as 96900 unless a significant, separately identifiable E/M service is provided. If so, append modifier 25 to the E/M code.
  • Direct physician supervision is typically required (the physician must be present in the office suite and immediately available), though exact supervision rules may vary by Medicare Administrative Contractor (MAC) and commercial payers.
  • Do not use 96900 for targeted excimer laser therapy. Excimer laser treatments are specifically coded using 96920-96922 based on the total treatment area in square centimeters.

Associated ICD-10 Codes